Bain Capital Life Sciences Investors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-346,545
| Closed | -$10M | – | 21 |
|
|
2025
Q4 | $10M | Hold |
346,545
| – | – | 0.77% | 15 |
|
|
2025
Q3 | $2.69M | Sell |
346,545
-2
| -0% | -$15 | 0.18% | 18 |
|
|
2025
Q2 | $2.56M | Hold |
346,547
| – | – | 0.32% | 19 |
|
|
2025
Q1 | $2.98M | Hold |
346,547
| – | – | 0.44% | 19 |
|
|
2024
Q4 | $12.4M | Hold |
346,547
| – | – | 1.46% | 14 |
|
|
2024
Q3 | $16.4M | Hold |
346,547
| – | – | 1.7% | 11 |
|
|
2024
Q2 | $17.4M | Hold |
346,547
| – | – | 1.91% | 11 |
|
|
2024
Q1 | $38.8M | Hold |
346,547
| – | – | 3.12% | 11 |
|
|
2023
Q4 | $20.1M | Hold |
346,547
| – | – | 1.93% | 13 |
|
|
2023
Q3 | $11M | Hold |
346,547
| – | – | 1.23% | 20 |
|
|
2023
Q2 | $28.5M | Hold |
346,547
| – | – | 2.94% | 13 |
|
|
2023
Q1 | $35.6M | Hold |
346,547
| – | – | 4.45% | 8 |
|
|
2022
Q4 | $50.8M | Hold |
346,547
| – | – | 5.67% | 5 |
|
|
2022
Q3 | $58.6M | Hold |
346,547
| – | – | 6.99% | 3 |
|
|
2022
Q2 | $40M | Buy |
346,547
+85,666
| +33% | +$8.06M | 4.69% | 8 |
|
|
2022
Q1 | $26M | Buy |
260,881
+45,454
| +21% | +$5.31M | 2.53% | 11 |
|
|
2021
Q4 | $33.5M | Buy |
215,427
+67,600
| +46% | +$13.2M | 2.66% | 13 |
|
|
2021
Q3 | $34.9M | Hold |
147,827
| – | – | 2.16% | 14 |
|
|
2021
Q2 | $50.2M | Hold |
147,827
| – | – | 3.29% | 9 |
|
|
2021
Q1 | $59.8M | Buy |
147,827
+10,000
| +7% | +$4.85M | 3.39% | 9 |
|
|
2020
Q4 | $91.7M | Hold |
137,827
| – | – | 5.76% | 4 |
|
|
2020
Q3 | $64.2M | Hold |
137,827
| – | – | 5.98% | 5 |
|
|
2020
Q2 | $80.6M | Buy |
+137,827
| New | +$47.1M | 8.44% | 5 |
|
Other funds holding MRSN
Bain Capital Life Sciences Investors's MRSN Position: Q1 2026 in Review
Bain Capital Life Sciences Investors sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 346,545 shares — an estimated $10M sold.
Bain Capital Life Sciences Investors first reported a position in MRSN in Q2 2020 and held it in 23 quarters. The position peaked at $91.7M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Bain Capital Life Sciences Investors reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bain Capital Life Sciences Investors sold 346,545 Mersana Therapeutics shares in Q1 2026, an estimated $10M.
- Bain Capital Life Sciences Investors first reported a position in Mersana Therapeutics in Q2 2020 and held it in 23 quarters.
- Bain Capital Life Sciences Investors's Mersana Therapeutics position peaked at $91.7M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.